PharmaKure is a spin out from The University of Manchester. It is a clinical stage biopharmaceutical company dedicated to the treatment of neurodegenerative diseases. The company’s core activities are researching, developing, commercializing & repositioning drugs for the treatment of Alzheimer’s, Parkinson’s & rare prion diseases. An important aspect is the combination of repurposed drugs with proprietary diagnostic ‘biomarkers’ which allows targeted therapy, thereby giving better clinical outcomes
PharmaKure is a clinical stage company, undertaking human trials:
- ALZmetrix® is PharmaKure’s unique blood- biomarker assay. A clinical study is underway with Alzheimer’s Disease patients.
- A Phase 2a, multiple ascending dose clinical trial of PharmaKure’s lead drug candidate for Alzheimer’s Disease is underway.
- PARKmetrix® is PharmaKure’s propriety blood- biomarker assay for diagnosis of Parkinson’s Disease.
If you have any questions, feel free to contact us.